Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Rating of “Moderate Buy” by Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $7.25.

A number of analysts recently weighed in on the stock. Raymond James Financial started coverage on shares of Milestone Pharmaceuticals in a report on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 price objective on the stock. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Wells Fargo & Company decreased their target price on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Finally, Zacks Research lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th.

Insider Buying and Selling

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 36,500 shares of Milestone Pharmaceuticals stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $2.26, for a total transaction of $82,490.00. Following the sale, the chief executive officer owned 446,244 shares of the company’s stock, valued at $1,008,511.44. The trade was a 7.56% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.03% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Strategic Family Wealth Counselors L.L.C. acquired a new position in Milestone Pharmaceuticals during the 4th quarter valued at about $25,000. Eaton Financial Holdings Company LLC acquired a new stake in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $26,000. Welch & Forbes LLC bought a new position in shares of Milestone Pharmaceuticals in the first quarter valued at approximately $30,000. Bank of America Corp DE increased its stake in shares of Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after acquiring an additional 16,044 shares during the period. Finally, Cetera Investment Advisers acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Trading Down 2.3%

Shares of NASDAQ MIST opened at $1.29 on Wednesday. Milestone Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $3.06. The company has a market cap of $160.60 million, a price-to-earnings ratio of -1.90 and a beta of 0.97. The company has a current ratio of 9.18, a quick ratio of 9.09 and a debt-to-equity ratio of 1.61. The stock’s 50 day simple moving average is $1.46 and its 200 day simple moving average is $1.68.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The company had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $30.11 million. Equities research analysts expect that Milestone Pharmaceuticals will post -0.97 EPS for the current year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.